IONS vs. MDGL, ALKS, FOLD, GERN, UTHR, TEVA, BMRN, ALNY, APLS, and ELAN
Should you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Amicus Therapeutics (FOLD), Geron (GERN), United Therapeutics (UTHR), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), Apellis Pharmaceuticals (APLS), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical preparations" industry.
Madrigal Pharmaceuticals (NASDAQ:MDGL) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, community ranking, valuation and institutional ownership.
98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 23.9% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Ionis Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Ionis Pharmaceuticals received 229 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. However, 68.56% of users gave Madrigal Pharmaceuticals an outperform vote while only 60.09% of users gave Ionis Pharmaceuticals an outperform vote.
In the previous week, Madrigal Pharmaceuticals had 5 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 10 mentions for Madrigal Pharmaceuticals and 5 mentions for Ionis Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.06 beat Ionis Pharmaceuticals' score of 0.52 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.
Madrigal Pharmaceuticals has a beta of -0.47, meaning that its stock price is 147% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.
Madrigal Pharmaceuticals has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -46.32%. Madrigal Pharmaceuticals' return on equity of -90.29% beat Ionis Pharmaceuticals' return on equity.
Madrigal Pharmaceuticals currently has a consensus price target of $356.73, suggesting a potential upside of 84.52%. Ionis Pharmaceuticals has a consensus price target of $56.08, suggesting a potential upside of 34.83%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than Ionis Pharmaceuticals.
Summary
Madrigal Pharmaceuticals and Ionis Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Ionis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ionis Pharmaceuticals Competitors List
Related Companies and Tools
